FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL								
	OMB Number: 3235-0287								
l	Estimated average burden								
l	hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ROBERTS EIRY					2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX											all appl Direct Office	r (give title	ıg Pei	rson(s) to Is 10% O Other (wner	
(Last) (First) (Middle) 12780 EL CAMINO REAL					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2023											Α	below (n) Chief Med	ical	below) Officer	
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea				2A. Deemed Execution Date, if any (Month/Day/Year)			Co	Transaction Code (Instr							5) Secur Bener Owner Follow		cially d ving	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Co	Code		Amo	ount	(A) or (D)	F	rice		Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 01/31/2023					3		S		S ⁽¹⁾		1,	,457	D	\$	\$109.9887(2)		7 ⁽²⁾ 26,171			D	
		Tal		Derivativ (e.g., pu													wned	t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	on Date,	4. Transaction Code (Instr. 8) 5. Numb of Derivativ Securitie Acquired (A) or Dispose of (D) (Instr. 3, and 5)				Exp	ate Ex iration nth/Da	n Date				int of ities rlying ative ity (Instr.	8. Pric Deriva Securi (Instr.		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	ode V (A) (D)		(D)	Date Exercisa			Expiration Date		le	Amount or Number of Shares						

Explanation of Responses:

1. Sale of 1,457 shares of common stock issued upon vesting of 2,768 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,311) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Remarks:

/s/ Darin Lippoldt, Attorney-

02/02/2023

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$109.07 to \$110.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.